Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Novo Nordisk's diabetes drug

Novo Nordisk has received approval from the US FDA for its type 2 diabetes treatment, Victoza (liraglutide)

Danish pharmaceutical company, Novo Nordisk has announced it has been granted marketing authorisation from the US Food and Drug Administration (FDA) for its type 2 diabetes treatment, Victoza (liraglutide).

Victoza is approved for use in addition to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.

"The US approval of Victoza represents a major advancement in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe." said Lars Rebien Sørensen, president and CEO.

He continued: "We are convinced that Victoza will prove to be a valuable treatment option for people with type 2 diabetes in the US. The ability of Victoza to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."

Novo Nordisk plans to introduce Victoza to the US market within the next few weeks.

26th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics